Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation

Biochemical Pharmacology

Volumn 85, Issue 9, 2013, Pages 1398-1404

  Zhang, Chengyue ^a   Su, Zheng Yuan ^a   Khor, Tin Oo ^a   Shu, Limin ^a   Kong, Ah Ng Tony ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

DNA methylation; Epigenetics; Nrf2; Prostate cancer; Sulforaphane

Indexed keywords

BISULFITE; DNA; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; HISTONE ANTIBODY; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 7; HISTONE H3; MESSENGER RNA; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL LEVEL; CHEMOPROPHYLAXIS; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; EPIGENETICS; GENE ACTIVATION; GENE EXPRESSION; GENE SEQUENCE; GENOME ANALYSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION;

ANIMALS; ANTICARCINOGENIC AGENTS; CELL LINE, TUMOR; CPG ISLANDS; EPIGENESIS, GENETIC; MALE; METHYLATION; MICE; NF-E2-RELATED FACTOR 2; PROSTATIC NEOPLASMS; THIOCYANATES;

EID: 84875746160     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.02.010     Document Type: Article

References (67)

1. R. Siegel, E. Ward, O. Brawley, and A. Jemal Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61 2011 212 236
2. B. Kumar, S. Koul, L. Khandrika, R.B. Meacham, and H.K. Koul Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype Cancer Res 68 2008 1777 1785
3. A. Minelli, I. Bellezza, C. Conte, and Z. Culig Oxidative stress-related aging: a role for prostate cancer? Biochim Biophys Acta 1795 2009 83 91
4. A.M. De Marzo, A.K. Meeker, S. Zha, J. Luo, M. Nakayama, and E.A. Platz Human prostate cancer precursors and pathobiology Urology 62 2003 55 62
5. B.P. Yu Cellular defenses against damage from reactive oxygen species Physiol Rev 74 1994 139 162
6. F. Balkwill, and A. Mantovani Inflammation and cancer: back to Virchow? Lancet 357 2001 539 545
7. A.M. De Marzo, E.A. Platz, S. Sutcliffe, J. Xu, H. Gronberg, and C.G. Drake Inflammation in prostate carcinogenesis Nat Rev Cancer 7 2007 256 269
8. A. Federico, F. Morgillo, C. Tuccillo, F. Ciardiello, and C. Loguercio Chronic inflammation and oxidative stress in human carcinogenesis Int J Cancer 121 2007 2381 2386
9. T. Nguyen, P.J. Sherratt, and C.B. Pickett Regulatory mechanisms controlling gene expression mediated by the antioxidant response element Annu Rev Pharmacool Toxicol 43 2003 233 260
10. H. Motohashi, and M. Yamamoto Nrf2-Keap1 defines a physiologically important stress response mechanism Trends Mol Med 10 2004 549 557
11. A. Kobayashi, T. Ohta, and M. Yamamoto Unique function of the Nrf2-Keap1 pathway in the inducible expression of antioxidant and detoxifying enzymes Methods Enzymol 378 2004 273 286
12. C. Chen, and A.N. Kong Dietary chemopreventive compounds and ARE/EpRE signaling Free Radic Biol Med 36 2004 1505 1516
13. M.K. Kwak, N. Wakabayashi, and T.W. Kensler Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers Mutat Res 555 2004 133 148
14. K.W. Kang, S.J. Lee, and S.G. Kim Molecular mechanism of Nrf2 activation by oxidative stress Antioxid Redox Signal 7 2005 1664 1673
15. T. Nguyen, P. Nioi, and C.B. Pickett The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress J Biol Chem 284 2009 13291 13295
16. Y. Li, and A.K. Jaiswal Regulation of human NAD(P)H:quinone oxidoreductase gene. Role of AP1 binding site contained within human antioxidant response element J Biol Chem 267 1992 15097 15104
17. R.S. Friling, S. Bergelson, and V. Daniel Two adjacent AP-1-like binding sites form the electrophile-responsive element of the murine glutathione S-transferase Ya subunit gene Proc Natl Acad Sci U S A 89 1992 668 672
18. M. Ramos-Gomez, M.K. Kwak, P.M. Dolan, K. Itoh, M. Yamamoto, and P. Talalay Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in Nrf2 transcription factor-deficient mice Proc Natl Acad Sci U S A 98 2001 3410 3415
19. T.O. Khor, M.T. Huang, A. Prawan, Y. Liu, X. Hao, and S. Yu Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer Cancer Prev Res (Phila) 1 2008 187 191
20. A. Barve, T.O. Khor, S. Nair, K. Reuhl, N. Suh, and B. Reddy Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice Int J Cancer 124 2009 1693 1699
21. A. Barve, T.O. Khor, K. Reuhl, B. Reddy, H. Newmark, and A.N. Kong Mixed tocotrienols inhibit prostate carcinogenesis in TRAMP mice Nutr Cancer 62 2010 789 794
22. D.A. Frohlich, M.T. McCabe, R.S. Arnold, and M.L. Day The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis Oncogene 27 2008 4353 4362
23. S. Yu, T.O. Khor, K.L. Cheung, W. Li, T.Y. Wu, and Y. Huang Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice PLoS ONE 5 2010 e8579
24. E. Devinoy, and M. Rijnkels Epigenetics in mammary gland biology and cancer J Mammary Gland Biol Neoplasia 15 2010 1 4
25. S.B. Baylin DNA methylation and gene silencing in cancer Nat Clin Pract Oncol 2 1 2005 S4 S11
26. J. Lopez, M. Percharde, H.M. Coley, A. Webb, and T. Crook The context and potential of epigenetics in oncology Br J Cancer 100 2009 571 577
27. M. Nakayama, M.L. Gonzalgo, S. Yegnasubramanian, X. Lin, A.M. De Marzo, and W.G. Nelson GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer J Cell Biochem 91 2004 540 552
28. C. Jeronimo, R. Henrique, M.O. Hoque, E. Mambo, F.R. Ribeiro, and G. Varzim A quantitative promoter methylation profile of prostate cancer Clin Cancer Res 10 2004 8472 8478
29. S.R. Morey, D.J. Smiraglia, S.R. James, J. Yu, M.T. Moser, and B.A. Foster DNA methylation pathway alterations in an autochthonous murine model of prostate cancer Cancer Res 66 2006 11659 11667
30. S.M. Pulukuri, and J.S. Rao CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2 Oncogene 25 2006 4559 4572
31. T.J. Walton, G. Li, R. Seth, S.E. McArdle, M.C. Bishop, and R.C. Rees DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines Prostate 68 2008 210 222
32. T.Y. Kim, Y.J. Bang, and K.D. Robertson Histone deacetylase inhibitors for cancer therapy Epigenetics 1 2006 14 23
33. M.T. McCabe, J.A. Low, S. Daignault, M.J. Imperiale, K.J. Wojno, and M.L. Day Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer Cancer Res 66 2006 385 392
34. K. Miyamoto, T. Ushijima, and Diagnostic therapeutic applications of epigenetics Jpn J Clin Oncol 35 2005 293 301
35. T. Suzuki, and N. Miyata Epigenetic control using natural products and synthetic molecules Curr Med Chem 13 2006 935 958
36. A.T. Hauser, and M. Jung Targeting epigenetic mechanisms: potential of natural products in cancer chemoprevention Planta Med 74 2008 1593 1601
37. S.M. Meeran, A. Ahmed, and T.O. Tollefsbol Epigenetic targets of bioactive dietary components for cancer prevention and therapy Clin Epigenetics 1 2010 101 116
38. M.Z. Fang, Y. Wang, N. Ai, Z. Hou, Y. Sun, and H. Lu Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines Cancer Res 63 2003 7563 7570
39. M. Pandey, S. Shukla, and S. Gupta Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells Int J Cancer 126 2010 2520 2533
40. T.O. Khor, Y. Huang, T.Y. Wu, L. Shu, J. Lee, and A.N. Kong Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation Biochem Pharmacol 82 2011 1073 1078
41. K.L. Cheung, and A.N. Kong Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention AAPS J 12 2010 87 97
42. E. Ho, J.D. Clarke, and R.H. Dashwood Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention J Nutr 139 2009 2393 2396
43. M. Valko, D. Leibfritz, J. Moncol, M.T. Cronin, M. Mazur, and J. Telser Free radicals and antioxidants in normal physiological functions and human disease Int J Biochem Cell Biol 39 2007 44 84
44. J.K. Kundu, and Y.J. Surh Nrf2-Keap1 signaling as a potential target for chemoprevention of inflammation-associated carcinogenesis Pharm Res 27 2010 999 1013
45. W. Li, and A.N. Kong Molecular mechanisms of Nrf2-mediated antioxidant response Mol Carcinog 48 2009 91 104
46. D.D. Zhang Mechanistic studies of the Nrf2-Keap1 signaling pathway Drug Metab Rev 38 2006 769 789
47. Z.Y. Su, L. Shu, T.O. Khor, J.H. Lee, F. Fuentes, and A.N. Kong A Perspective on dietary phytochemicals and cancer chemoprevention: oxidative stress, Nrf2, and epigenomics Top Curr Chem 2012
48. Y. Huang, T.O. Khor, L. Shu, C.L. Saw, T.Y. Wu, and N. Suh A gamma-tocopherol-rich mixture of tocopherols maintains Nrf2 expression in prostate tumors of TRAMP mice via epigenetic inhibition of CpG methylation J Nutr 142 2012 818 823
49. G. Shen, C. Xu, R. Hu, M.R. Jain, A. Gopalkrishnan, and S. Nair Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin Mol Cancer Ther 5 2006 39 51
50. R. Garg, S. Gupta, and G.B. Maru Dietary curcumin modulates transcriptional regulators of phase I and phase II enzymes in benzo[a]pyrene-treated mice: mechanism of its anti-initiating action Carcinogenesis 29 2008 1022 1032
51. Y.S. Keum, T.O. Khor, W. Lin, G. Shen, K.H. Kwon, and A. Barve Pharmacokinetics and pharmacodynamics of broccoli sprouts on the suppression of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: implication of induction of Nrf2, HO-1 and apoptosis and the suppression of Akt-dependent kinase pathway Pharm Res 26 2009 2324 2331
52. J.W. Fahey, X. Haristoy, P.M. Dolan, T.W. Kensler, I. Scholtus, and K.K. Stephenson Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors Proc Natl Acad Sci U S A 99 2002 7610 7615
53. C. Xu, M.T. Huang, G. Shen, X. Yuan, W. Lin, and T.O. Khor Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2 Cancer Res 66 2006 8293 8296
54. G. Garcia-Manero, S. Assouline, J. Cortes, Z. Estrov, H. Kantarjian, and H. Yang Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia Blood 112 2008 981 989
55. W.K. Rasheed, R.W. Johnstone, and H.M. Prince Histone deacetylase inhibitors in cancer therapy Expert Opin Investig Drugs 16 2007 659 678
56. E.A. Griffiths, and S.D. Gore DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes Semin Hematol 45 2008 23 30
57. S. Majid, A.A. Dar, A.E. Ahmad, H. Hirata, K. Kawakami, and V. Shahryari BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer Carcinogenesis 30 2009 662 670
58. S.M. Meeran, S.N. Patel, and T.O. Tollefsbol Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines PLoS ONE 5 2010 e11457
59. M.C. Myzak, P.A. Karplus, F.L. Chung, and R.H. Dashwood A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase Cancer Res 64 2004 5767 5774
60. M.C. Myzak, K. Hardin, R. Wang, R.H. Dashwood, and E. Ho Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells Carcinogenesis 27 2006 811 819
61. M.C. Myzak, P. Tong, W.M. Dashwood, R.H. Dashwood, and E. Ho Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects Exp Biol Med (Maywood) 232 2007 227 234
62. M.C. Myzak, W.M. Dashwood, G.A. Orner, E. Ho, and R.H. Dashwood Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice FASEB J 20 2006 506 508
63. N.K. Saxena, and D. Sharma Epigenetic reactivation of estrogen receptor: promising tools for restoring response to endocrine therapy Mol Cell Pharmacol 2 2010 191 202
64. S.M. Meeran, S.N. Patel, Y. Li, S. Shukla, and T.O. Tollefsbol Bioactive dietary supplements reactivate ER expression in ER-negative breast cancer cells by active chromatin modifications PLoS ONE 7 2012 e37748
65. D. Sharma, J. Blum, X. Yang, N. Beaulieu, A.R. Macleod, and N.E. Davidson Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells Mol Endocrinol 19 2005 1740 1751
66. M. Macaluso, C. Cinti, G. Russo, A. Russo, and A. Giordano pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer Oncogene 22 2003 3511 3517
67. S.V. Singh, R. Warin, D. Xiao, A.A. Powolny, S.D. Stan, and J.A. Arlotti Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells Cancer Res 69 2009 2117 2125